PENTAPHARMA
ActiveSummary
PENTAPHARMA has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €38,418 and a net result of €2,769. Equity is growing by about 28% per year across the filed financial years. Its solvency ranks better than 47% of 8,547 sector peers (NACE 73, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
25-07
Gazette deed
Appointments: TRYPSTEEN Kristiaan (director) and UNIPHARM (director)Permanent representative: VANDENBERGHE Chris · Legal form clause · Capital conversion15 facts ▸
- General meeting, “buitengewone algemene vergadering, eenparigheid van stemmen” (deed in Dutch)
- Legal form clause, “van rechtswege, besloten vennootschap” (deed in Dutch)
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Other provision, “wettelijke reserve” (deed in Dutch)
- Other provision, “eigen vermogensrekening niet-opgevraagde inbrengen” (deed in Dutch)
- Capital conversion, “beschikbare eigen vermogensrekeningen” (deed in Dutch)
- Registered office clause, “Vlaams Gewest” (deed in Dutch)
- Director appointment, TRYPSTEEN Kristiaan (director)
- Director appointment, UNIPHARM (director)
- Permanent representative, VANDENBERGHE Chris
- Other provision, “eenparigheid van stemmen, modaliteiten bestuursmandaat in breedste betekenis” (deed in Dutch)
- Amendment of the articles, 25
- +3 further facts in this act
About the unread acts
Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.